Komori
Share Issuance and Disposal9267Genky DrugStores Co.,Ltd.Retail

Notice Regarding the Granting of Stock Options (Share Acquisition Rights)

The company will submit to the shareholders' meeting a proposal to issue stock acquisition rights as stock options to its inside directors and employees, as well as the directors and employees of its subsidiaries. The total number to be issued will be capped at 1,500, representing a maximum of 150,000 underlying shares and maximum dilution of 0.49%.

Worth reading
51Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
0.49
% (dilution rate)
Wording
Conditional
How definitive the wording is.

Details of issuance or disposal

Issuance of share acquisition rights as stock options

Who receives how much

Up to 150,000 shares of the company's common stock (100 shares per stock acquisition right)

The company's inside directors and employees, and the directors and employees of its subsidiaries. The number of inside directors is expected to be 5, with allocations capped at 500 stock acquisition rights.

The lower thin line represents the existing number of shares to which these shares will be added.

The stock acquisition rights will be issued for no consideration. The exercise price will be calculated by multiplying the average closing price on each trading day in the month preceding the month containing the issue date by 1.05. If this amount is below the closing price on the issue date, the closing price on the issue date will apply.
発行済株式総数

Maximum 0.49%

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Exercise price
The initial exercise price will be the average closing price for the month preceding the month containing the issue date multiplied by 1.05. However, the closing price on the issue date will serve as the floor. Adjustment provisions will apply in the event of a stock split, consolidation or other similar event.
Exercise period
A period to be determined by the Board of Directors, beginning on the date 2 years after the date of the Board of Directors' resolution determining the offering terms of the stock acquisition rights and ending within 5 years thereafter.
Number of Stock Acquisition Rights
Total issuance capped at 1,500 stock acquisition rights. The number of outstanding unexercised rights is Not disclosed.
Reason for acquisition without consideration
If a merger in which the company is the disappearing company, a company split in which it is the splitting company, or a share exchange or share transfer in which it becomes a wholly owned subsidiary is approved by the shareholders' meeting or the Board of Directors, the company may acquire the stock acquisition rights for no consideration on a date specified by the Board of Directors.
Conditions on transfer restrictions

Restricted stock is stock awarded as compensation that cannot be sold during a specified period, with the restrictions lifted once the applicable conditions are met.

Conditions for lifting transfer restrictions
As a general rule, the holder must remain in office or employment. The rights may continue to be exercised in the event of retirement upon expiration of a term of office, retirement upon reaching the mandatory retirement age, or other circumstances recognized by the company as having a legitimate reason. In the event of death, the holder's heirs may exercise the rights.
Categories and Number of Persons Covered
5 inside directors of the company, with allocations capped at 500 stock acquisition rights. The number of employees of the company and directors and employees of its subsidiaries, and their allocation amounts, are Not disclosed.
Intended allottee's holding policy
The acquisition of the stock acquisition rights through transfer requires approval from the Company's Board of Directors.
Basis for determining the amount to be paid
The exercise price will be calculated by multiplying the average closing price of the company's common stock on the Tokyo Stock Exchange on each trading day in the month preceding the month containing the issue date by 1.05. If the calculated amount is below the closing price on the issue date, the closing price on the issue date will apply.
Procedures under the Corporate Code of Conduct
The proposal is scheduled to be submitted to the 9th Annual General Meeting of Shareholders on 10 September 2026. At meetings of the Board of Directors and the Audit & Supervisory Committee held on 11 September 2025, resolutions were passed on the policy for determining individual director compensation and other remuneration, based on the recommendations of the voluntary Compensation Committee.
Details of issuance or disposal
ItemDetails
Type of issuance or disposalIssuance of share acquisition rights as stock options
Number of shares to be issued or disposed ofUp to 150,000 shares of the company's common stock (100 shares per stock acquisition right)
Issue price and disposal priceThe stock acquisition rights will be issued for no consideration. The exercise price will be calculated by multiplying the average closing price on each trading day in the month preceding the month containing the issue date by 1.05. If this amount is below the closing price on the issue date, the closing price on the issue date will apply.
Intended allotteeThe company's inside directors and employees, and the directors and employees of its subsidiaries. The number of inside directors is expected to be 5, with allocations capped at 500 stock acquisition rights.
Intended allottee's holding policyThe acquisition of the stock acquisition rights through transfer requires approval from the Company's Board of Directors.
Dilution RateMaximum 0.49%
Basis for determining the amount to be paidThe exercise price will be calculated by multiplying the average closing price of the company's common stock on the Tokyo Stock Exchange on each trading day in the month preceding the month containing the issue date by 1.05. If the calculated amount is below the closing price on the issue date, the closing price on the issue date will apply.
Exercise priceThe initial exercise price will be the average closing price for the month preceding the month containing the issue date multiplied by 1.05. However, the closing price on the issue date will serve as the floor. Adjustment provisions will apply in the event of a stock split, consolidation or other similar event.
Exercise periodA period to be determined by the Board of Directors, beginning on the date 2 years after the date of the Board of Directors' resolution determining the offering terms of the stock acquisition rights and ending within 5 years thereafter.
Number of Stock Acquisition RightsTotal issuance capped at 1,500 stock acquisition rights. The number of outstanding unexercised rights is Not disclosed.
Conditions for lifting transfer restrictionsAs a general rule, the holder must remain in office or employment. The rights may continue to be exercised in the event of retirement upon expiration of a term of office, retirement upon reaching the mandatory retirement age, or other circumstances recognized by the company as having a legitimate reason. In the event of death, the holder's heirs may exercise the rights.
Reason for acquisition without considerationIf a merger in which the company is the disappearing company, a company split in which it is the splitting company, or a share exchange or share transfer in which it becomes a wholly owned subsidiary is approved by the shareholders' meeting or the Board of Directors, the company may acquire the stock acquisition rights for no consideration on a date specified by the Board of Directors.
Categories and Number of Persons Covered5 inside directors of the company, with allocations capped at 500 stock acquisition rights. The number of employees of the company and directors and employees of its subsidiaries, and their allocation amounts, are Not disclosed.
Procedures under the Corporate Code of ConductThe proposal is scheduled to be submitted to the 9th Annual General Meeting of Shareholders on 10 September 2026. At meetings of the Board of Directors and the Audit & Supervisory Committee held on 11 September 2025, resolutions were passed on the policy for determining individual director compensation and other remuneration, based on the recommendations of the voluntary Compensation Committee.
Items this document does not state (14)
Total issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateTotal number of issued sharesTransfer restriction periodTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMost recent equity financingMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The stock acquisition rights will be issued to further motivate and boost morale toward improving the company's consolidated performance and to support business expansion. The company also states that grants to directors are consistent with the purpose of stock options and constitute appropriate compensation and other remuneration.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Granting of Stock Options (Share Acquisition Rights) | Genky DrugStores Co.,Ltd. (9267) timely disclosure | Komori